Can I Take Resveratrol with Trulicity (Dulaglutide)?

What Is Trulicity and How Does It Work?

Dulaglutide, sold as Trulicity, is a once-weekly injectable GLP-1 receptor agonist approved by the FDA in September 2014 for type 2 diabetes. It also carries an indication for reducing major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, based on the REWIND trial.

GLP-1 Mechanism in Brief

Dulaglutide binds GLP-1 receptors on pancreatic beta cells, amplifying glucose-dependent insulin secretion. It simultaneously suppresses glucagon, slows gastric emptying, and reduces appetite through central hypothalamic signaling. Because insulin release is glucose-dependent, hypoglycemia is uncommon when dulaglutide is used as monotherapy.

REWIND Trial Numbers

The REWIND trial (N=9,901, median 5.4-year follow-up) showed dulaglutide 1.5 mg weekly reduced the primary composite cardiovascular outcome by 12% versus placebo (hazard ratio 0.88, 95% CI 0.79 to 0.99, P=0.026) [1]. Mean HbA1c reduction was 0.61 percentage points greater with dulaglutide at 24 months.

Pharmacokinetic Profile Relevant to Interactions

Dulaglutide is a large peptide-Fc fusion protein. It is not metabolized by cytochrome P450 enzymes. Elimination occurs through proteolytic degradation into amino acids, identical to endogenous protein catabolism. This detail matters because many supplement-drug interactions operate through CYP enzyme competition, and that pathway simply does not apply to dulaglutide [2].

What Is Resveratrol and Why Do People Take It?

Resveratrol is a stilbene polyphenol produced by several plants, most notably Vitis vinifera (red grapes), Polygonum cuspidatum (Japanese knotweed, the primary commercial source), and peanuts. It gained mainstream attention after early sirtuin-activation research in the 2000s linked it to lifespan extension in yeast and mice.

Claimed Benefits and the Evidence Gap

Proposed human benefits include improved insulin sensitivity, reduced fasting glucose, cardiovascular protection, anti-inflammatory effects, and longevity signaling via SIRT1 activation. The evidence in humans is considerably weaker than in preclinical models. A 2018 meta-analysis of 17 randomized controlled trials (N=783) found resveratrol significantly reduced fasting glucose (mean difference -7.87 mg/dL, 95% CI -13.15 to -2.59) and insulin resistance as measured by HOMA-IR, but effect sizes were modest and study quality was heterogeneous [3].

Resveratrol and CYP Enzymes

This is the pharmacokinetic concern most often raised about resveratrol co-administration with other drugs. In vitro studies show resveratrol can inhibit CYP3A4, CYP2C9, and CYP2D6. At the doses used in those assays, concentrations were far higher than what typical oral supplementation achieves in human plasma. A 2010 pharmacokinetic study found that 1,000 mg/day resveratrol for 4 weeks produced peak plasma concentrations of roughly 2.4 µmol/L in healthy adults, well below the IC50 values needed to meaningfully inhibit CYP3A4 in vivo [4]. At the 200 to 500 mg doses found in most OTC resveratrol capsules, clinically significant CYP inhibition is unlikely.

Because dulaglutide bypasses CYP metabolism entirely, even if resveratrol did inhibit CYP3A4 to a clinically relevant degree, that pathway would not affect dulaglutide exposure. The pharmacokinetic interaction risk between these two agents is low.

Estrogenic Activity of Resveratrol

Resveratrol binds both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), acting as a selective estrogen receptor modulator (SERM)-like compound. At low concentrations it tends to act as an estrogen agonist at ERβ and a weak antagonist or partial agonist at ERα. This property is not relevant to dulaglutide's mechanism, which involves GLP-1 receptors and has no known interaction with estrogen signaling. The estrogenic activity becomes relevant to individual patient history, specifically in patients with hormone-sensitive conditions such as estrogen receptor-positive breast cancer, endometriosis, or uterine fibroids, where a prescribing physician should weigh resveratrol use regardless of which diabetes medication is involved [5].

The Pharmacodynamic Interaction: Additive Blood Glucose Lowering

The more clinically relevant question is whether resveratrol's glucose-lowering effect adds meaningfully to dulaglutide's effect, and whether that combination could produce hypoglycemia.

How Resveratrol Lowers Glucose

Resveratrol appears to reduce blood glucose through at least three mechanisms. First, it activates AMPK, increasing glucose uptake in skeletal muscle and reducing hepatic glucose output. Second, SIRT1 activation improves insulin receptor sensitivity in adipocytes and hepatocytes. Third, resveratrol may reduce intestinal glucose absorption by inhibiting sodium-glucose cotransporter 1 (SGLT1) in some preclinical models.

Magnitude of Effect in Human Trials

The glucose-lowering effect of resveratrol in humans is real but modest. The 2018 meta-analysis cited above showed a mean fasting glucose reduction of approximately 7.87 mg/dL [3]. By comparison, dulaglutide 1.5 mg weekly reduced HbA1c by 1.1 to 1.4 percentage points in the AWARD-5 trial (N=1,098) versus 0.39 percentage points for sitagliptin [6]. In terms of absolute fasting glucose, dulaglutide's effect is 5 to 10 times larger than what resveratrol typically provides in trials.

Hypoglycemia Risk Assessment

When dulaglutide is used without insulin or a sulfonylurea, hypoglycemia rates are low, approximately 1 to 3% in monotherapy trials. Adding resveratrol's modest glucose-lowering effect does not dramatically shift this risk. The combination becomes more clinically significant if the patient is also taking insulin, a sulfonylurea (glipizide, glimepiride, glyburide), or a meglitinide. In those scenarios, the additive glucose lowering from resveratrol could increase hypoglycemia risk in a meaningful way. Patients on dulaglutide plus insulin or a secretagogue should discuss resveratrol use with their prescriber before starting.

HealthRX Hypoglycemia Risk Framework for Resveratrol + Dulaglutide:

| Patient Regimen | Estimated Additive Hypo Risk from Resveratrol | Recommended Action | |---|---|---| | Dulaglutide monotherapy | Low | SMBG for 2 to 4 weeks; inform prescriber | | Dulaglutide + metformin | Low to minimal | SMBG for 2 weeks; inform prescriber | | Dulaglutide + SGLT2 inhibitor | Low | SMBG for 2 weeks; inform prescriber | | Dulaglutide + sulfonylurea | Moderate | Consult prescriber before starting resveratrol | | Dulaglutide + basal insulin | Moderate | Consult prescriber before starting resveratrol | | Dulaglutide + sulfonylurea + insulin | Higher | Do not start without prescriber guidance |

What the Major Guidelines Say About Supplements in Diabetes

The American Diabetes Association 2024 Standards of Care state directly: "There is no clear evidence of benefit from vitamin or mineral supplementation in people with diabetes who do not have underlying deficiencies... Routine supplementation with antioxidants, such as vitamins E and C and carotene, is not advised... Evidence does not support the use of cinnamon, curcumin, vitamin D, magnesium, or other supplements for glucose lowering in people with diabetes" [7]. Resveratrol is not specifically named, but the general recommendation is to disclose all supplements to the diabetes care team.

The ADA also notes: "Providers should discuss the use of dietary supplements with all people with diabetes because they may be beneficial in select cases but may also be harmful or interfere with medications."

No major guideline currently recommends resveratrol as an adjunct to any diabetes medication, including GLP-1 receptor agonists. That absence of recommendation is not the same as a prohibition. It means the evidence base has not yet matured enough for guideline endorsement.

Gastric Emptying, Absorption, and Timing Considerations

Dulaglutide slows gastric emptying, particularly in the first few hours after injection. This pharmacodynamic effect peaks in the early weeks of treatment and partially diminishes over time. Slower gastric emptying could in theory alter the absorption rate of oral supplements, including resveratrol, by delaying when resveratrol reaches the small intestine for absorption.

Does This Matter Clinically?

Resveratrol absorption is already highly variable and relatively low. Oral bioavailability ranges from roughly 25 to 35% in pharmacokinetic studies, and resveratrol is rapidly metabolized to glucuronide and sulfate conjugates in the intestinal wall and liver. A modest further delay in gastric transit caused by dulaglutide would be unlikely to produce a clinically significant change in total resveratrol exposure. No dedicated pharmacokinetic study has evaluated resveratrol absorption specifically under dulaglutide co-administration.

If a patient is concerned about absorption, taking resveratrol with the largest meal of the day, which is typically when gastric emptying effects are most relevant, may be counterproductive. Taking it at a different time from the main meal should have minimal impact given the lack of a specific interaction mechanism.

Resveratrol Dosing and Product Quality Concerns

Most over-the-counter resveratrol products contain trans-resveratrol, the biologically active isomer, from Polygonum cuspidatum extract. Doses range widely: 50 mg capsules at the low end, up to 1,000 to 3,000 mg products marketed for longevity.

Doses Used in Clinical Trials

Human clinical trials have most often used 150 to 1,000 mg/day. The CALERIE-related resveratrol work and the RESMENA trial used 500 to 1,000 mg/day ranges. A 2020 randomized controlled trial in type 2 diabetes patients (N=66, 8 weeks) using 1,000 mg/day resveratrol showed significant reductions in fasting glucose (mean -15.1 mg/dL), HbA1c (-0.54%), and total cholesterol versus placebo [8].

Third-Party Testing

The supplement industry is not required to prove efficacy or purity before sale. Resveratrol products frequently fail third-party testing for label accuracy. NSF International, USP, and ConsumerLab.com independently verify supplement contents. Patients should select resveratrol products carrying one of these certification seals to ensure they are actually receiving the stated dose of trans-resveratrol.

Monitoring Protocol When Taking Both

Self-monitoring is the practical anchor for safe co-use. Specific guidance for a patient starting resveratrol while already established on dulaglutide:

Blood Glucose Monitoring

Check fasting blood glucose on the morning of and the morning after starting resveratrol. Continue daily fasting checks for 2 weeks, then revert to the patient's usual monitoring schedule if no hypoglycemic episodes occur. A reading below 70 mg/dL (3.9 mmol/L) meets the American Diabetes Association's Level 1 hypoglycemia threshold and should be reported to the prescriber [9].

Symptoms to Watch

Symptoms of mild hypoglycemia include shakiness, sweating, palpitations, hunger, and light-headedness. These can be mistaken for gastrointestinal side effects of dulaglutide, which include nausea, vomiting, and diarrhea, particularly in the first 4 to 8 weeks of Trulicity use. Distinguishing GI side effects from hypoglycemia symptoms requires checking actual blood glucose, not relying on symptoms alone.

When to Discontinue Resveratrol

Stopping resveratrol is appropriate if the patient experiences two or more hypoglycemic episodes within 14 days of starting the supplement, if their prescriber advises against it based on full medication review, or if they begin a new diabetes medication that increases hypoglycemia risk.

Special Populations

Patients with Hormone-Sensitive Conditions

Resveratrol's SERM-like estrogenic activity is a separate concern from its glucose effects. Women with a personal or family history of hormone-sensitive breast cancer, current or past estrogen receptor-positive cancer, endometriosis, or uterine fibroids should discuss resveratrol use with their oncologist or gynecologist, independent of their diabetes regimen.

Patients on Anticoagulants or Antiplatelet Agents

Resveratrol inhibits platelet aggregation in vitro and may enhance the effects of warfarin, clopidogrel, or aspirin. Patients with type 2 diabetes frequently take antiplatelet therapy for cardiovascular risk reduction. If a patient is on dulaglutide for its cardiovascular benefit per REWIND and also on antiplatelet therapy, adding high-dose resveratrol (above 500 mg/day) warrants discussion with the prescriber.

Renal Impairment

Dulaglutide does not require dose adjustment for renal impairment, and the FDA label supports its use through severe chronic kidney disease stages. Resveratrol's renal effects are not well characterized in humans with significant CKD. Until more data are available, patients with eGFR <30 mL/min/1.73m2 should exercise caution with high-dose resveratrol and inform their nephrologist.

Summary of the Interaction Profile

Combining resveratrol with Trulicity does not produce a pharmacokinetic interaction because dulaglutide bypasses CYP metabolism entirely. A mild pharmacodynamic interaction exists because both agents lower blood glucose, though resveratrol's glucose-lowering effect is small relative to dulaglutide's. Resveratrol's estrogenic activity is unrelated to dulaglutide but is relevant to individual patient history. At standard OTC doses of 200 to 500 mg/day, resveratrol is unlikely to cause meaningful hypoglycemia in patients on dulaglutide monotherapy or dulaglutide plus metformin, but is more concerning in patients also taking sulfonylureas or insulin.

Patients already taking both should check fasting blood glucose daily for 2 weeks after adding resveratrol and report any reading below 70 mg/dL to their prescriber. Patients who have not yet started resveratrol should inform their diabetes care team before doing so, consistent with ADA 2024 guidance [7].